Navigation

Breast cancer (early) - trastuzumab: audit criteria

The audit is to assist NHS trusts to determine whether the service is implementing, and is in compliance with, the NICE technology appraisal: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer.

This page was last updated: 28 December 2010

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.